Ikena Oncology is a targeted oncology company that develops novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its programs focus on genetically defined or biomarker-driven cancers, enabling it to target specific patient populations that are most likely to respond to treatment with its product candidates. The company has a deep pipeline of wholly owned and partnered programs, supported by top-tier investors and partners, to advance and broaden its portfolio of novel, patient-directed oncology therapies.